Positions
- Professor of Surgery
-
Division of Surgical Oncology
Baylor College of Medicine
- Professor
-
Molecular Virology & Microbiology, Pathology & Immunology
Baylor College of Medicine
Addresses
- Molecular Surgeon Research Center R430 (Lab)
-
Baylor College of Medicine
Houston, TX, 77030
United States
Phone: (713) 798-1816
Vascular Surgery
- Alkek Building for Biomedical Research (Office)
-
Baylor College of Medicine
Houston, TX, 77030
United States
Phone: (713) 798-1765
Education
- Advanced Training from Emory University
- 01/1997 - Atlanta, GA, United States
- PhD from Emory University
- 01/1996 - Atlanta, GA, GA, United States
- MS from University of Texas at El Paso
- 01/1990 - El Paso, TX
- MD from Southeast University Medical School
- Nanjing, China
- M.D. from Nanjing University
- 01/1986 - Nanjing, China, People's Rep
Honors & Awards
- Molecular Surgeon Research Achievement Award
- Baylor College of Medicine
- Norton Rose Fulbright Faculty Excellence Award for Teaching & Evaluation
- Baylor College of Medicine
Professional Interests
- Pancreatic cancer immunotherapy
- Pancreatic cancer pathogenesis
- Nanoparticle targeted delivery
Professional Statement
My lab is interested in developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both preventive and therapeutic purposes. In preclinical studies, VLPs formed by structural proteins are highly immunogenic and capable of inducing protective immunity against various viral infections. We have modified vaccine immunogens into chimeric HIV VLPs which contain influenza viral surface glycoprotein HA or other immunologically functional molecules. We have shown that the chimeric HIV VLPs can induce enhanced humoral and cellular immune responses against HIV in a mouse model.
We have also studied the basic mechanisms of VLP-induced humoral and cellular immune responses, and other factors that affect these responses. For example, we found that VLP vaccines activate conventional B2 cells and promote B cell differentiation to IgG2a producing plasma cells; that VLP vaccines travel to the lymph nodes upon immunization and can be directly visualized by optical imaging techniques; and that intradermal immunization generates improved responses and might be a preferable delivery route for viral and cancer immunotherapeutic studies involving VLPs.
Since dendritic cells (DCs) have long been known to be pivotal in initiating immune responses, we are also interested in how VLPs modulate DC functions and will evaluate the efficacy of VLP-pulsed DC vaccines. In addition, we are interested in testing the efficacy of modified chimeric VLP oral-mucosal immunization in non-human primates.
Pancreatic cancer has one of the highest mortality rates and ranks as the third leading cause of cancer death in America. Survival is poor because there are no reliable tests for early diagnosis and no effective therapies to treat metastatic disease. There is a need to better understand the molecular mechanisms of pancreatic cancer tumorigenesis and to develop effective treatments. My lab currently focuses on the study of key molecules in pancreatic cancer, including Mesothelin (MSLN), Trop2 and Fibrinogen (FBG), and in their mechanisms of regulation. We are also interested in the involvement of microRNAs (miR-198) in pancreatic cancer, and how their dysregulation leads to pathogenesis. We are currently exploring tumor-associated molecule targeted therapies and RNA interference delivery by liposomes and PLGA nanoparticles in vivo. In addition, we are interested in developing non-infectious chimeric virus-like particles (VLPs) as a vaccine candidate for pancreatic cancer. Our group has shown that vaccinating mice with chimeric virus-like particles containing MSLN significantly inhibited tumor progression, suggesting a new therapeutic vaccine strategy whereby MSLN is targeted to attempt to control pancreatic cancer progression. We are also employing pancreatic cancer patient-derived xenografts (PDX) mouse model to study the potential of our various therapeutic regimens.
Websites
YouTube Video
Modulation of miR-198
From the labs to commercialization
Baylor College of Medicine graduate starts Speratum CR to bring his own discovery to cancer patients
Videos
Modulation of miR-198
Modulation of miR-198
Selected Publications
-
Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q. " Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. " PLoS ONE. 2013 ; 8 (5) : e63702.
Pubmed PMID: 23704933. -
Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. " Mesothelin confers pancreatic cancer cell resistance to TNF-a-induced apoptosis through Akt/PI3K/NF-?B activation and IL-6/Mcl-1 overexpression. " Mol. Cancer. 2011 ; 10 : 106.
Pubmed PMID: 21880146. -
Marin-Muller C, Rios A, Anderson D, Siwak E, Yao Q. " Complete and repeatable inactivation of HIV-1 viral particles in suspension using a photo-labeled non-nucleoside reverse transcriptase inhibitor. " J. Virol. Methods. 2013 Apr ; 189 (1) : 125-8.
Pubmed PMID: 23384676. -
Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. " Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. " Carcinogenesis. 2011 Jul ; 32 (7) : 1013-24.
Pubmed PMID: 21515913.
Memberships
- American Association for the Advancement of Science
- American Association for Cancer Research
- Association for Academic Surgery
- American Association of Immunologists
- Society of Chinese Bioscientists in America
- American Society for Virology
- National Academy of Inventors
- Fellow
Log In to edit your profile